FDA Approves Novavax COVID-19 Vaccine with Age and Risk-Based Limitations

The U.S. Food and Drug Administration has granted approval for Novavax’s COVID-19 vaccine, branded as Nuvaxovid, but with specific usage limitations. The vaccine is now authorized for individuals 65 years and older, as well as for those between the ages of 12 and 64 who have underlying medical conditions that heighten their risk for severe COVID-19. The approval comes after a comprehensive review of multiple clinical trials, but further studies will be required for pediatric use.

Although the license allows for commercial distribution, several conditions are attached. Nuvaxovid will be available only in single-dose pre-filled syringes and must be stored at refrigerated temperatures with a three-month shelf life. The FDA also imposed strict reporting and manufacturing requirements, including mandatory submission of samples for lot release and ongoing oversight of any product deviations.

In addition to manufacturing stipulations, the FDA requires extensive postmarketing surveillance. Novavax must report adverse events like myocarditis, pericarditis, atrial fibrillation, and cerebrovascular accidents within 15 days for a period of three years. Several long-term studies must also be conducted to evaluate these risks and any potential long-term effects, including dedicated safety monitoring in pregnant women and young children.

Pediatric use has been deferred for those under 12 years of age, pending the results of ongoing studies. The company must provide final reports extending as far as 2032, with studies covering children from birth to under 12 years. Further postmarketing trials will assess the safety and efficacy of the vaccine in adults aged 50 to 64 without high-risk conditions, to evaluate broader use potential. All promotional materials must remain consistent with FDA-approved labeling and avoid unverified comparative claims.

Associated documents for this story are available in our Public Information Archive.

Article by multiple RFHC contributors, based upon information from the U.S. Food and Drug Administration approval letter issued May 16, 2025.

---